Skip to content

Fungal paronychia

Fungal hand infections: Candida paronychia, deep space infections, and increasing incidence in periprosthetic joint infections.

Overview

Hand infections encompass a diverse array of entities with significant potential for serious morbidity [2]. Management of acute hand infections necessitates a combination of surgical intervention, specifically incision and drainage, alongside antibiotic therapy tailored to the causative organism and infection severity [3]. While acute paronychial abscesses are generally treated operatively, no consensus currently exists regarding the optimal surgical technique [5]. Large, prospective studies are required to definitively identify the best treatment regimens for both acute and chronic paronychia [4].

Fungal infections present distinct management challenges, particularly in immunocompromised patients. Although the majority of patients with fungal tenosynovitis of the hand and upper extremity are successfully treated with surgical debridement and antimicrobial therapy, a 30% recurrence rate underscores the critical need for close post-treatment follow-up [6]. Management of fungal osteomyelitis and fungal septic arthritis remains difficult, with historically poor outcomes attributed to a lack of evidence-based treatment guidelines [9].

Pharmacologic efficacy varies by pathogen. Oral terbinafine is the most effective agent for dermatophyte onychomycosis [7], whereas itraconazole or fluconazole may be more effective than terbinafine for Candida onychomycosis [7]. Future high-quality studies are needed to develop standardized guidelines for the management of fungal periprosthetic joint infections [8].

Anatomy & Pathophysiology

Hand infections encompass a diverse array of entities with potential for serious morbidity [2]. Fungal tenosynovitis of the hand and upper extremity represents a rare diagnosis [6], while management of fungal osteomyelitis and fungal septic arthritis remains challenging, particularly in immunocompromised patients [9]. Historically, outcomes for these conditions have been poor due to a lack of evidence-based treatment guidelines [9].

Therapeutic Agents: Oral terbinafine is the most effective agent for dermatophyte onychomycosis [7], whereas itraconazole or fluconazole may be more effective than terbinafine for Candida onychomycosis [7]. Surgical Management: Two-stage exchange remains the most commonly used surgical approach for fungal periprosthetic joint infection [13], though the reliability of one- and three-stage exchange requires further evaluation due to small sample sizes [13]. Outcomes: A recurrence rate of 30% has been observed in patients treated for fungal tenosynovitis of the hand and upper extremity [6].

Classification

Hand infections encompass a diverse clinical spectrum with potential for serious morbidity, including paronychia [1, 2]. Acute and chronic paronychia are distinct entities requiring specific treatment regimens [4]. Acute paronychial abscesses are generally treated operatively [5]. Neonates with oral self-soothing behaviors may be at risk for developing paronychia of mixed anaerobic and aerobic infections [12]. Methicillin-resistant Staphylococcus aureus is the most common bacteria cultured from acute hand infections [10].

Fungal Pathology: Fungal tenosynovitis of the hand and upper extremity is a rare diagnosis [6]. A recurrence rate of 30% has been observed in patients treated for fungal tenosynovitis of the hand and upper extremity [6]. Fungal osteomyelitis and fungal septic arthritis are challenging to manage, especially in immunocompromised patients [9]. Historically, outcomes for fungal osteomyelitis and fungal septic arthritis have been poor due to a lack of evidence-based treatment guidelines [9].

Antifungal Agents: Oral terbinafine is the most effective agent for dermatophyte onychomycosis [7]. Itraconazole or fluconazole may be more effective than terbinafine for Candida onychomycosis [7].

Other Considerations: The management of fungal hand infections remains complicated by the rarity of the diagnosis and the specific challenges posed to immunocompromised hosts.

Clinical Presentation

Hand infections encompass a diverse array of entities with the potential for serious morbidity [2]. Specific risk profiles exist for certain populations; neonates exhibiting oral self-soothing behaviors are at increased risk for developing paronychia characterized by mixed anaerobic and aerobic infections [12]. In terms of microbiology, Methicillin-resistant Staphylococcus aureus has been identified as the most common bacteria cultured from acute hand infections at urban medical centers [10].

Deep-seated fungal infections present distinct clinical challenges. Fungal tenosynovitis of the hand and upper extremity carries a recurrence rate of 30% [6]. Management of fungal osteomyelitis and fungal septic arthritis is particularly challenging, especially in immunocompromised patients [9]. Historically, outcomes for these conditions have been poor due to a lack of evidence-based treatment guidelines [9].

Investigations

Laboratory: Empiric antibiotic coverage for acute hand infections should routinely cover methicillin-resistant Staphylococcus aureus, which was the most common bacteria cultured from acute hand infections at an urban medical center [10]. Neonates with oral self-soothing behaviors may be at higher risk for developing paronychia of mixed anaerobic and aerobic infections [12]. Hand infections include a diverse array of entities with potential for serious morbidity [2].

Other Considerations: Treatment of fungal tenosynovitis of the hand and upper extremity requires surgical debridement and antimicrobial therapy, with a recurrence rate of 30% observed in treated patients [6]. Close post-treatment follow-up is required for these patients [6]. Management of fungal osteomyelitis and fungal septic arthritis is challenging, especially in immunocompromised patients, and historically outcomes have been poor due to a lack of evidence-based treatment guidelines [9]. Two-stage exchange remains the most commonly used surgical approach for fungal periprosthetic joint infection, though the reliability of one- and three-stage exchange needs further evaluation due to small sample sizes [13].

Therapeutic Agents: Oral terbinafine is the most effective agent for dermatophyte onychomycosis [7]. Itraconazole or fluconazole may be more effective than terbinafine for Candida onychomycosis [7]. Treatment options for fungal nail infections include topical agents for mild disease, oral systemic agents for moderate to severe disease, and combination therapy strategies for severe, recurrent, and persistent disease [11].

Treatment

Management of hand infections necessitates a combination of surgical intervention, specifically incision and drainage, alongside antibiotic therapy tailored to the causative organism and infection severity [3]. Acute paronychial abscesses are generally treated operatively, though there is currently no consensus on the optimal surgical technique for acute paronychia [5]. Large, prospective studies are required to identify the most effective treatment regimens for both acute and chronic paronychia [4].

Non-Operative: Topical agents are indicated for mild fungal nail infections, whereas oral systemic agents are reserved for moderate to severe disease [11]. Combination therapy strategies are utilized for severe, recurrent, and persistent fungal nail infections [11].

Operative: Indications: Surgical debridement is indicated for fungal tenosynovitis of the hand and upper extremity, as well as for acute paronychial abscesses [6]. Management of fungal osteomyelitis and fungal septic arthritis remains challenging, particularly in immunocompromised patients [9].

Surgical Approach / Technique: Surgical debridement combined with antimicrobial therapy successfully treats the majority of patients with fungal tenosynovitis [6].

Adjuncts: Close post-treatment follow-up is mandatory for fungal tenosynovitis due to a documented recurrence rate of 30% [6].

Other Considerations: Oral terbinafine is the most effective agent for dermatophyte onychomycosis, while itraconazole or fluconazole may be more effective than terbinafine for Candida onychomycosis [7]. Historically, outcomes for fungal osteomyelitis and fungal septic arthritis have been poor due to a lack of evidence-based treatment guidelines [9]. Future high-quality studies are needed to develop standardized guidelines for the management of fungal periprosthetic joint infections [8].

Complications

Wound complications: Hand infections encompass a diverse array of entities with potential for serious morbidity [2]. Treatment of acute hand infections requires a combination of surgical intervention (incision and drainage) and appropriate antibiotic therapy tailored to the organism and infection severity [3]. Empiric antibiotic coverage for acute hand infections should routinely cover methicillin-resistant Staphylococcus aureus, the most common bacteria cultured from acute hand infections at an urban medical center [10]. While acute paronychial abscesses are generally treated operatively, there is no consensus on the best surgical technique [5].

Infection (PJI): Management of fungal osteomyelitis and fungal septic arthritis is challenging, especially in immunocompromised patients [9]. Historically, outcomes for fungal osteomyelitis and fungal septic arthritis have been poor due to a lack of evidence-based treatment guidelines [9]. Future high-quality studies are needed to develop standardized guidelines for the management of fungal periprosthetic joint infections [8].

Other Considerations: Although the majority of patients with fungal tenosynovitis of the hand and upper extremity were successfully treated with surgical debridement and antimicrobial therapy, a recurrence rate of 30% highlights the need for close post-treatment follow-up [6]. Oral terbinafine is the most effective agent for dermatophyte onychomycosis [7], whereas itraconazole or fluconazole may be more effective than terbinafine for Candida onychomycosis [7]. Large, prospective studies are needed to identify the best treatment regimen for acute and chronic paronychia [4].

Recovery

Light activity (weeks): Evidence does not specify a timeline for light activity or return to desk work following fungal paronychia or onychomycosis treatment.

Full activity (months): Evidence does not specify a timeline for manual work, sport, or full range of motion return.

Complete recovery / outcome plateau (months): Evidence does not specify a timeline for the stabilization of pain, strength, or final functional outcomes.

Rehabilitation protocol: Evidence does not provide specific data on physical therapy phasing, immobilisation duration, weight-bearing progression, or brace removal timing for these conditions.

Functional milestones: Evidence does not report validated patient-reported outcome measure (PROM) trajectories or benchmark scores (e.g., Constant, ASES, WOMAC) for recovery.

Other Considerations: Large, prospective studies are needed to identify the best treatment regimen for acute and chronic paronychia [4]. While acute paronychial abscesses are generally treated operatively, there is no consensus on the best surgical technique [5]. Although the majority of patients with fungal tenosynovitis of the hand and upper extremity were successfully treated with surgical debridement and antimicrobial therapy, a recurrence rate of 30% highlights the need for close post-treatment follow-up [6]. Oral terbinafine is the most effective agent for dermatophyte onychomycosis [7]. Itraconazole or fluconazole may be more effective than other agents for Candida onychomycosis [7]. Treatment options for fungal nail infections include topical agents for mild disease [11], oral systemic agents for moderate to severe disease [11], and combination therapy strategies for severe, recurrent, and persistent disease [11].

Key Evidence

  • [L5] This article reviews the clinical spectrum and microbiology of the most common infections of the hand and discusses current concepts for their treatment to increase physician awareness of diagnosis and management. (10.1302/2058-5241.4.180082)
  • [L5] Hand infections include a diverse array of entities with potential for serious morbidity. (10.1016/j.jhsa.2011.05.035)
  • [L5] Treatment requires a combination of surgical intervention (incision and drainage) and appropriate antibiotic therapy tailored to the organism and infection severity. (10.1016/j.jhsa.2014.03.031)
  • [L5] Large, prospective studies are needed to identify the best treatment regimen for acute and chronic paronychia. (10.5435/jaaos-22-03-165)
  • [L5] While acute paronychial abscesses are generally treated operatively, there is no consensus on the best surgical technique. (10.1016/j.jhsa.2011.11.021)
  • [L4] Although the majority of patients were successfully treated with surgical debridement and antimicrobial therapy, a recurrence rate of 30% highlights the need for close post-treatment follow-up. (10.1016/j.jhsa.2016.11.014)
  • [L5] Oral terbinafine is the most effective agent for dermatophyte onychomycosis, while itraconazole or fluconazole may be more effective for Candida onychomycosis. (10.1016/j.jhsa.2008.05.028)
  • [L5] Future high-quality studies are needed to develop standardized guidelines for the management of fungal PJI. (10.5435/jaaos-d-18-00331)
  • [L5] Management of fungal osteomyelitis and fungal septic arthritis is challenging, especially in immunocompromised patients, and historically outcomes have been poor due to a lack of evidence-based treatment guidelines. (10.5435/jaaos-22-06-390)
  • [L4] Methicillin-resistant Staphylococcus aureus was the most common bacteria cultured from these infections, and empiric antibiotic coverage should routinely cover methicillin-resistant S aureus. (10.1016/j.jhsa.2013.03.013)
  • [L5] Treatment options include topical agents for mild disease, oral systemic agents for moderate to severe disease, and combination therapy strategies for severe, recurrent, and persistent disease. (10.1016/j.jhsa.2013.11.017)
  • [L4] Neonates with oral self-soothing behaviors may be more at risk for developing paronychia of mixed anaerobic and aerobic infections. (10.1177/1558944717692092)
  • [L2] Two-stage exchange remains the most commonly used surgical approach, though the reliability of one- and three-stage exchange needs further evaluation due to small sample sizes. (10.1186/s12891-024-07616-6)

See Also

References

[1] Infections of the hand: an overview. EFORT Open Reviews. 2019. DOI: 10.1302/2058-5241.4.180082

[2] Hand Infections. The Journal of Hand Surgery. 2011. DOI: 10.1016/j.jhsa.2011.05.035

[3] Acute Hand Infections. The Journal of Hand Surgery. 2014. DOI: 10.1016/j.jhsa.2014.03.031

[4] Acute and Chronic Paronychia of the Hand. Journal of the American Academy of Orthopaedic Surgeons. 2014. DOI: 10.5435/jaaos-22-03-165

[5] Acute Paronychia. The Journal of Hand Surgery. 2012. DOI: 10.1016/j.jhsa.2011.11.021

[6] A Rare Diagnosis: Recognizing and Managing Fungal Tenosynovitis of the Hand and Upper Extremity. The Journal of Hand Surgery. 2017. DOI: 10.1016/j.jhsa.2016.11.014

[7] Current Management of Onychomycosis. The Journal of Hand Surgery. 2008. DOI: 10.1016/j.jhsa.2008.05.028

[8] Diagnosis and Management of Fungal Periprosthetic Joint Infections. Journal of the American Academy of Orthopaedic Surgeons. 2019. DOI: 10.5435/jaaos-d-18-00331

[9] Fungal Osteomyelitis and Septic Arthritis. Journal of the American Academy of Orthopaedic Surgeons. 2014. DOI: 10.5435/jaaos-22-06-390

[10] Epidemiology of Adult Acute Hand Infections at an Urban Medical Center. The Journal of Hand Surgery. 2013. DOI: 10.1016/j.jhsa.2013.03.013

[11] Fungal Nail Infections. The Journal of Hand Surgery. 2014. DOI: 10.1016/j.jhsa.2013.11.017

[12] Neonatal Acute Paronychia. HAND. 2017. DOI: 10.1177/1558944717692092

[13] The heavy burden and treatment challenges of fungal periprosthetic joint infection: a systematic review of 489 joints. BMC Musculoskeletal Disorders. 2024. DOI: 10.1186/s12891-024-07616-6

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International

Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees

Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.